Zacks Research Analysts Boost Earnings Estimates for Sanofi

Sanofi (NASDAQ:SNY) – Investment analysts at Zacks Research upped their FY2024 earnings per share estimates for Sanofi in a note issued to investors on Wednesday, November 13th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $4.31 for the year, up from their prior forecast of $4.12. The consensus estimate for Sanofi’s current full-year earnings is $4.29 per share. Zacks Research also issued estimates for Sanofi’s Q4 2024 earnings at $0.84 EPS, Q1 2026 earnings at $1.17 EPS and Q2 2026 earnings at $1.16 EPS.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Sanofi’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.55 earnings per share.

SNY has been the subject of a number of other reports. Argus lifted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Down 1.1 %

Sanofi stock opened at $48.00 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company’s 50-day moving average is $54.25 and its 200-day moving average is $52.22. The firm has a market capitalization of $121.82 billion, a PE ratio of 24.49, a P/E/G ratio of 1.22 and a beta of 0.61. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Institutional Trading of Sanofi

Institutional investors and hedge funds have recently bought and sold shares of the stock. ProShare Advisors LLC lifted its holdings in Sanofi by 7.1% in the first quarter. ProShare Advisors LLC now owns 19,197 shares of the company’s stock valued at $933,000 after buying an additional 1,268 shares during the period. Blair William & Co. IL acquired a new stake in shares of Sanofi during the 1st quarter worth approximately $204,000. Jacobi Capital Management LLC increased its stake in shares of Sanofi by 10.4% in the 1st quarter. Jacobi Capital Management LLC now owns 5,503 shares of the company’s stock valued at $267,000 after acquiring an additional 518 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of Sanofi by 3.2% during the 1st quarter. Clearbridge Investments LLC now owns 172,214 shares of the company’s stock valued at $8,370,000 after acquiring an additional 5,411 shares during the period. Finally, Lake Street Advisors Group LLC grew its holdings in Sanofi by 24.8% in the first quarter. Lake Street Advisors Group LLC now owns 7,174 shares of the company’s stock worth $349,000 after purchasing an additional 1,426 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.